Summary of REMS@FDA Website Updates for July 2022

Summary of REMS@FDA Website Updates for July 2022 1. Zydelig (Idelalisib) REMS released July 6, 2022.  2. Ultomiris (ravulizumab-cwvz) REMS modified July 22, 2022 to change the REMS document to align with labeling and updated REMS materials to incorporate the revised logo capturing both intravenous and subcutaneous routes of administration. Manage Subscriptions  |  Unsubscribe All  |  Help This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA